Clinical trials: Gefitinib
Head and Neck Cancer, Carcinoma, Squamous Cell
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.
- Trial name
- NCT00233636
- Testing
- Iressa (Gefitinib), Radiotherapy
- Where
- 6 sites in Italy
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer, Brain Metastases
The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC
Brain metastasis is the most common neurological complication in tumor patients, and lung cancer is the most common tumor with brain metastasis.
- Trial name
- BRATR (NCT04193007)
- Testing
- molecular targeted therapies, Brain Radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Advanced Stage Non Small Cell Lung Cancer
Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
This study is a multicenter, randomized, open-label Phase II trial that compares reduced dose erlotinib 100mg daily and standard dose gefitinib 250mg daily in patients with advanced non-small cell lung cancer who harbor EGFR…
- Trial name
- NSCLC EGFR TKI (NCT01955421)
- Testing
- Erlotinib 100mg qd, Gefitinib 250mg qd
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Sun Yat-sen University
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
Gefitinib Long-term Survivor Study
The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
- Trial name
- NCT02932345
- Where
- 14 sites in China
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, EGFR Gene Mutation
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
The first-line treatment with single agent AZD3759 results in superior Progression Free Survival (PFS) compared to Standard of Care (SoC) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI), in patients with…
- Conditions
- Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases
- Trial name
- BM (NCT03653546)
- Testing
- AZD3759, Erlotinib, Gefitinib
- Where
- 58 sites in China, Singapore and 2 more
- Volunteers
- 492 people
- Sponsor
- Alpha Biopharma (Jiangsu) Co., Ltd.
Non Small Cell Lung Cancer
Randomized Gefitinib Trial
Patients with locally advanced (IIIB with effusion) or metastatic non-small cell lung cancer (NSCLC), EGFR FISH positive, candidate for a first-line platinum-based chemotherapy will be considered eligible for the trial.
- Trial name
- RANGE (NCT00807066)
- Testing
- Gefitinib, Platinum
- Where
- Italy
- Volunteers
- 1 people
- Sponsor
- Fondazione Humanitas per la Ricerca
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer
Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Randomized phase III trial to compare the effectiveness of combination chemotherapy plus radiation therapy with or without gefitinib in treating unresectable stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00020709
- Testing
- cisplatin, docetaxel, etoposide
- Where
- United States
- Volunteers
- 840 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
To explore the survival benefit of the gefitinib combined with radiotherapy as adjuvant therapy for completely resected patients with Pathological stage IIIA-N2 NSCLC harbouring sensitive mutations of EGFR.
- Trial name
- NCT03381430
- Testing
- Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.